- Do you own shares of Hi-Tech Pharmacal Co., Inc. (NASDAQ GS: HITK )?
- Did you purchase any of your shares prior to August 27, 2013?
- Do you think the proposed buyout price is too low?
- Do you want to discuss your rights?
A better-than-expected consumer confidence report for August couldn't shake concern that a U.S. airstrike in Syria could escalate Middle East wars, disrupting oil supplies.
Akorn expands into generic oral and nasal care through an acquisition that values its target's equity at $640 million.
Stock futures are diving Tuesday as investors grow concerned about potential U.S. military intervention in Syria.